Winarko Luminturahardjo, Hustorio Aliongko Simamora, Evan Kurniawan Gianto


Background: Treatment of COVID-19 patients with comorbid like diabetes mellitus as more consequences such as greater mortality risk and prolonged hospitalization. One of the reasons is caused by a hypercoagulable state. Aim: To prove the difference in coagulation parameters of platelet count, C-Reactive Protein, and D-dimer between Covid-19 patients with diabetes comorbidity and without diabetes, and to analyze the correlation between coagulation parameters with the stage of pneumonia caused by Covid19. Methods: The design is a cross-sectional study. The sample was collected from patients registered whose hospitalized in an isolation ward at Panti Nirmala Hospital Malang from April to October 2021. Coagulation parameters (platelet counts, C-reactive protein (CRP), and D-dimer level) were measured from 134 patients, divided between 40 patients with diabetes mellitus and 94 patients without diabetes mellitus. Statistical analysis was performed by software SPSS 24, the version year 2016. Results: Among 134 COVID-19 patients who had diabetes and no diabetes comorbidity, there are results: no significant difference in average platelet counts between the two groups (p=0.763), and the difference in C-reactive protein is significant between the two groups (p=0.076), and the difference of D-dimer level is not significant between them (p=0.593). There is a positive correlation between CRP and D-dimer level with the stage of COVID19 pneumonia (r=0.000 and r=0.134), and on the other hand, there is a negative correlation between platelet counts with the stage of pneumonia (r=-0.126). Conclusion: COVID-19 patients hospitalized with diabetes mellitus tend to have more severe conditions marked by a higher level of coagulation parameters and correlate with the severity of pneumonia.

Save to Mendeley

Full Text:



World Health Organization. 2022. WHO Coronavirus (COVID-19) Dashboard. WHO (COVID-19) Homepage.

Sriram K, Insel PA. Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purigenic receptors as drivers and candidate therapeutic targets. 2021. Physiol Rev 101: 545-567;

Vajari MK, Shirin M, Sigaroodi AP, Akbari ME, Abolghasemi H, et al. Cell Biol Int.2021;45: 1832-1850; doi:10.1002/cbin.11623

Apicella M, Campopiana MC, Mantuana M, Mazoni L, Cappeli A, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Available at:;

Riset Kesehatan Dasar Indonesia (2013). Laporan Hasil Riset Kesehatan Dasar (Riskesdas).

Stengenga ME, Crabben van der SN, Blumer RM, Levi M, Meijers JCM, et al. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. The American Society of Hematology 2008; 112 (1): 82-89, doi 10.1182/blood-2007-11-121723

Lim S; Bae JH; Kwon HS, Nauck MA. COVID-19 and diabetes melitus: from pathophysiology to clinical management. Endocrinology 2021; 17: 11-29; 10.1058/s4/574-020-00455-4

Farha MA, Mulia FA, Thanaraj TA, Kavalakatt S, Ali H, et al. Impact of diabetes in patients diagnosed with COVID-19. Frontiers in Immunology 2020; 11: 576818; doi: 10.3389/fimmu.2020.576818

Ortega AG, Rosa de la D, Oscullo G, Villegas DC, Reyes RL, et al. Coagulation disorders and thromboembolic disease in COVID-19: Review of current evidence insearch of a better approach. J Thorac Dis 2021;13(2):1239-1255;

Wijaya I, Andhika R, Huang I. Hypercoagulable state in COVID-19 with diabetes mellitus and obesity: Is therapeutic-dose or higher-dose anticoagulant thromboprophylaxis necessary. Clinical Research & Reviews 2020; 14: 1241-1242;

Ugwueze CV, Ezeokpo BC, Nnolim BL, Agim EA, Anikpo NC, et al. COVID-19 and diabetes mellitus: The link and clinical implications. Dubai Diabetes Endocrinol J 2020;26:69-77; doi:10.1159/000511354

Barazoni R, Zanetti M, Davanzo G, Kiwanuka E, Carraro P, et al. Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: Correlation with plasma glucagon concentrations. J Clin Endocrinol Metab 2000; 85:3121-3125

Banchini F, Cattaneo GM, Capelli P. Serum ferritin levels in inflammation: a retrospective comparative analysis between COVID-19 and emergency surgical non-COVID-19 patients. World Journal of Emergency Surgery 2021;16:9;

Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis;

Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol 2020;2:e594-602;

Arshad AR, Khan I, Shahzad K, Arshad M, Haider SJ, et al. Association of inflammatory markers with mortality in COVID-19 infection. J Coll Physicians Surg Pak 2020; 30(Supp2):S158-S163;

Zhang J, Hao Y, Ou W, Ming F, Liang G, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J Transl Med 2020;18:406;

Miri C, Charii H, Bouazzaoui MA, Brem FL, Boulouiz S, et al. D-dimer level and diabetes in the COVID-19 infection. Clinical and Applied Thrombosis/Hemostasis 2021;27:1-4; doi:10.1177/10760296211

Salabei JK, Fishman TJ, Asnake ZT, Ali A, Iyer UG. COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation. Heart & Lung 2021;50:357-360;,hrtlng.2021.01.011

Bao C, Tao X, Cui W, Yi B, Pan X, et al. SARS-CoV-2 induced thrombocytopenia as an important biomarker signifcantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients. Exp Hematol Oncol (2020) 9:16;

Litninov RI, Evtugina NG, Peshkova AD, Svetlana IS, Andrianova IA, et al. Altered platelet and coagulation function in moderate to severe COVID 19. Scientific Reports 2021;11:16290;

Bellkina DV, Malysheva ES, Petrov AV, Nekrasova TA, Nekaeva ES, et al. COVID-19 in Patients with Diabetes: Clinical Course, Metabolic Status, Inflammation and Coagulation Disorder. CTM 2020;12(5):6-16; doi:10.17691/stm2020.12.5.01

Debi H, Itu ZT, Amin MT, Hussain F, Hossain MS. Association of serum C-reactive protein (CRP) and D-dimer concentration on the severity of COVID-19 cases with or without diabetes: a systematic review and metaanalysis. Expert Review of Endocrinology and Metabolism;EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM;

Koh H, Moh AMC, Yeoh E, Lin Y, Low AKM, et al. Diabetes predicts severity of COVID‐19 infection in a retrospective cohort: A mediatory role of the inflammatory biomarker C‐reactive protein. J Med Virol 2021:1-10; doi:10.1002/jmv.26837

Pangaribuan JP, Pase MA. Correlation between HbA1C and D-dimer in Type 2 Diabetic with COVID-19 Patients. Journal of Endocrinology, Tropical Medicine, and Infectious Disease 2021;3(4): 145-151;

Mishra Y, Pathak BK, Mohakuda SS, Tilak TVSVGK, Sen S, et al. Relation of D-dimer levels of COVID-19 patients with diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2020;14:1927-1930;

Chen S, Liu H, Li T, Huang R, Gui R. Correlation analysis of coagulation dysfunction and liver damage in patients with novel coronavirus pneumonia: a single-center, retrospective, observational study. Do Upsala Journal Of Medical Sciences 2020: 125(4), 293-296; UPSALA JOURNAL OF MEDICAL SCIENCES 2020; 125(4):293–296;

Avci BS, Kaya A, Sumbul HE, Icme F, Yesilagac H, et al. Relationship between Covid-19-associated pneumonia severity with coagulopathy and mortality. Cukurova Med J 2021;46(2):540-547; doi:10.17826/cumj.864023

Arslan S, Ugurlu S, Bulut G, Akkurt I. The Association Between Plasma D-Dimer Levels And Community Acquired Pneumonia. Clinics 2010;65(6):593-7; doi:10.1590/S1807-59322010000600006

Carubbi F, Salvati L, Alunno A, Maggi F, Borghi E. Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID 19: data from two Italian COVID 19 units. Scientific Reports 2021;11:4863;